5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

To be considered for this study, you would generally need to be at least 18 years old and have bowel cancer that has been confirmed by lab tests to be advanced, has spread, and can't be removed by surgery. Crucially, your cancer must also have a specific genetic change called the KRAS G12C mutation. We are looking for patients who are generally less able to tolerate strong chemotherapy treatments, which might include those aged 75 or older, or younger patients with other health concerns that affect their physical ability.

You would not be able to join if you are fit enough for typical strong chemotherapy treatments, or if you have severe health problems with your liver, lungs, or certain other conditions. You also can't have had previous treatment specifically for cancer that has spread, though prior chemotherapy given after surgery (adjuvant chemotherapy) is generally okay if it finished more than six months ago. You would also need to have generally normal organ function (like your blood counts, kidneys, and liver).

If you decide to take part, you would receive the study medicines in cycles, every two weeks. This involves some medicines given through a drip into your vein (5-FU and Panitumumab) and one taken as a tablet by mouth every day (Sotorasib). These treatments would continue until the cancer starts to grow again, or if the side effects become too difficult to manage. You would have regular appointments to monitor your health, check for side effects, and have scans to see how the cancer is responding to treatment. The doctors and nurses will keep a close eye on you throughout the study. We expect to include patients for about 36 months, though your individual treatment duration would depend on how you respond to the medicines.